Cross reactive cellular immune response to HCV genotype 1 and 4 antigens among genotype 4 exposed subjects.

ABSTRACT:

Background

Hepatitis C Virus (HCV) infection is a global health burden particularly in Egypt, where HCV genotype 4a (GT-4a) predominates. The prevention and control of HCV infection will remain a challenge until the development of an effective vaccine that protects against different genotypes. Several HCV GT-1-based vaccines are in different stages of clinical trials, but antigenic differences could make protection against other genotypes problematic. In this regard, data comparing the cell-mediated immune (CMI) response to different HCV genotypes are limited. We aimed to ex vivo investigate whether GT-1-based vaccine may protect against HCV GT-4 infections. This was carried out on samples collected from genotype 4 infected/exposed subjects.

Methods/principal findings

The CM

SUBMITTER: Galal IF 

PROVIDER: S-EPMC4076338 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature